P/E ratio for MediciNova (MNOV)
P/E ratio as of April 2024 (TTM): -5.28
According to MediciNova's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.28. At the end of 2022 the company had a P/E ratio of -7.32.
P/E ratio history for MediciNova from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -7.32 | -44.28% |
| 2021 | -13.1 | -25.05% |
| 2020 | -17.5 | -24.56% |
| 2019 | -23.2 | 5.25% |
| 2018 | -22.1 | 12.62% |
| 2017 | -19.6 | 7.3% |
| 2016 | -18.3 | 69.86% |
| 2015 | -10.8 | 38.01% |
| 2014 | -7.79 | -27.15% |
| 2013 | -10.7 | 330.61% |
| 2012 | -2.48 | 78.32% |
| 2011 | -1.39 | -51.78% |
| 2010 | -2.89 | -31.04% |
| 2009 | -4.19 | 377.03% |
| 2008 | -0.8785 | -20.37% |
| 2007 | -1.10 | -70.76% |
| 2006 | -3.77 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 26.5 | -601.64% | 🇨🇭 Switzerland |
 Eli Lilly LLY | 134 | -2,628.62% | 🇺🇸 USA |
 Sanofi SNY | 15.5 | -393.95% | 🇫🇷 France |
 Titan Pharmaceuticals
TTNP | -12.3 | 132.92% | 🇺🇸 USA |
 Alkermes ALKS | 18.8 | -456.06% | 🇮🇪 Ireland |
 Teva Pharmaceutical Industries TEVA | -6.63 | 25.47% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.